A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).

Venclexta (venetoclax) - Roche, AbbVie

azacitidine - Generic mfg.

emavusertib (CA-4948) - Curis, Dr. Reddy’s

https://meetings.asco.org/abstracts-presentations/238176/

Adolfo de la Fuente Burguera; Claudio Cerchione; Sebastian Scholl; Jan Moritz Middeke; Nitika Nitika; Maureen E Lane; Wanying Zhao; Steven Angelides; Reinhard von Roemeling; Uwe Platzbecker

Apr 25, 2024